This combination enhanced the frequency of NY-ESO-1-specific effector CD8+ T cells producing IFN-γ and promoted lymphocyte migration to the tumor infiltrate, ultimately controlling the development of an established melanoma in the murine model [279]. The gene discussed is CD8A; the disease is neoplasm.